Some people use very small 'microdoses' to get benefits with fewer side effects, taken weekly or every other day
Treatment also markedly reduced circulating aldosterone
Pricing is transparent, with one-time purchases and subscription discounts, but it reflects the Price-Safety Trap, in which low cost substitutes for proven medical care
Future: Dedicated NASH Phase 3 Trial Expected Timeline IF Retatrutide Approved for Obesity/Diabetes (2028): 2027-2028: Dedicated NASH Phase 3 trial begins Population: Biopsy-confirmed NASH with fibrosis (F1-F3) Primary endpoint: NASH resolution without worsening fibrosis Baseline and Week 72-96 liver biopsies Duration: 18-24 months minimum 2029-2030: Trial results published 2030-2031: FDA approval decision for NASH indication Why This Matters Current Reality: Only one FDA-approved medication exists for NASH resmetirom (Rezdiffra), approved March 2024
In an experimental study in rats using a protocol of CR (40%, 23 months), it was noticed that mitochondrial state 4 increased with age (with subsequent high ROS production) in the ad libitum fed, but not in the CR group (Sohal et al., 1994)